PharmaShots

MAY 19, 2023

Alimera Acquires Rights from EyePoint Pharmaceuticals to Commercialise Yutiq in the US Date: May 19, 2023 | Tags: Alimera, EyePoint Pharmaceuticals, Yutiq, Iluvien, chronic non-infectious uveitis, US, Pharma Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A Date: May 19, 2023 | Tags: Sobi, Efanesoctocog Alfa, (..)

Medical Schools 40

Medical Schools FDA Immunization Vaccines 40

Pharmaceutical Technology

MAY 2, 2023

In contrast to ICIs, which are utilised against solid tumours, cell therapies and bispecifics have been transformational in the haematological cancer settings, with approvals across a range of leukaemias and lymphomas. Cost-related unmet needs also scored highly.

Immunization 52

Immunization Vaccines 52

pharmaphorum

DECEMBER 23, 2022

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S. Professional reception of the findings.

Immunization 52

Immunization Hospitals Vaccines 52

pharmaphorum

OCTOBER 4, 2022

The Biobank was launched in 2020, with an initial aim of enrolling at least 1,000 patients with locally advanced or metastatic solid tumours and haematologic malignancies undergoing standard of care therapy. Building a bank. The entire process takes place in the physician’s office, alongside a clinician.

Documentation 100

Documentation Data Entry HIPAA Insurance 100

European Pharmaceutical Review

DECEMBER 27, 2023

Building on success with haematological malignancies, CAR T-cell therapy holds promise for treating solid tumours. Building on success with haematological malignancies, CAR T-cell therapy holds promise for treating solid tumours. This is in addition to its considerable price tag. 6-8 Clinical recommendations also change.

Adverse Reactions 82

Adverse Reactions Immunization Medical Schools Chemotherapy 82